About Humanwell US
Humanwell Pharmaceutical US, Inc. is a Missouri-incorporated pharmaceutical research and development company that focuses on the development of novel therapies to address unmet medical needs. Humanwell US is an independent subsidiary company of Yichang Humanwell Pharmaceutical Co. LTD.
Yichang Humanwell
Yichang Humanwell Pharmaceutical Co. LTD, is a global market leader in anesthetic and pain medications. More than 4,000 employees work together to deliver products to over 20 countries, helping to make the world a healthier and happier place.
Our Timeline
2015.9: Founding of Humanwell US
2016.8: Grand opening of the laboratory
2016.12: DEA registrations obtained
2017.5: Tech transfer of developed oral products
2018.5: Branded Products Department established
2019.9: Lab expansion for NCE and complex injectables
2020.Q4: First ANDA filing
2020.Q4: First NCE compound enters GLP
2022.Q2: First ANDA Approval
2022.Q3: First 505(b)(2) project enters GLP
2023.Q1: First NDA project approved by FDA enters Phase I clinical trial
2023.Q3: Second ANDA Approval
